Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study

Affiliations

¹ Kojinkai Sapporo Skin Clinic, H&B plaza building 5F, S3 w2, Chuo-ku, Sapporo Hokkaido, 060-0063, Japan. Electronic address: osamu.nemo@gmail.com.
² Yanagibashi-Clinical Trial Center, Yanagibashi Hospital, Tokyo, Japan. Electronic address: nagashima@y-ctc.com.
³ Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan. Electronic address: sayama@m.ehime-u.ac.jp.
⁴ Shinanozaka Clinic, Medical Corporation Shinanokai, Tokyo, Japan. Electronic address: k-takazawa@shinanozaka-clinic.jp.

Randomized Controlled Trial

Nemoto Osamu et al. J Dermatol Sci. 2014 Sep.

. 2014 Sep;75(3):201-4.

doi: 10.1016/j.jdermsci.2014.05.007. Epub 2014 Jun 4.

¹ Kojinkai Sapporo Skin Clinic, H&B plaza building 5F, S3 w2, Chuo-ku, Sapporo Hokkaido, 060-0063, Japan. Electronic address: osamu.nemo@gmail.com.
² Yanagibashi-Clinical Trial Center, Yanagibashi Hospital, Tokyo, Japan. Electronic address: nagashima@y-ctc.com.
³ Department of Dermatology, Ehime University Graduate School of Medicine, Ehime, Japan. Electronic address: sayama@m.ehime-u.ac.jp.
⁴ Shinanozaka Clinic, Medical Corporation Shinanokai, Tokyo, Japan. Electronic address: k-takazawa@shinanozaka-clinic.jp.

No abstract available

Publication types